Key Insights

Highlights

Success Rate

91% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.8%

3 terminated out of 62 trials

Success Rate

91.4%

+4.9% vs benchmark

Late-Stage Pipeline

13%

8 trials in Phase 3/4

Results Transparency

28%

9 of 32 completed with results

Key Signals

9 with results91% success

Data Visualizations

Phase Distribution

39Total
Not Applicable (10)
Early P 1 (1)
P 1 (4)
P 2 (16)
P 3 (5)
P 4 (3)

Trial Status

Completed32
Unknown16
Withdrawn7
Terminated3
Recruiting2
Not Yet Recruiting1

Trial Success Rate

91.4%

Benchmark: 86.5%

Based on 32 completed trials

Clinical Trials (62)

Showing 20 of 20 trials
NCT07552779Phase 1RecruitingPrimary

A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir

NCT05160636Active Not Recruiting

A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza

NCT05164744Recruiting

Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors

NCT05077332Phase 2Completed

LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)

NCT04401436CompletedPrimary

COVID-19 Associated Lymphopenia Pathogenesis Study in Blood

NCT04347239Phase 2CompletedPrimary

Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19

NCT04969991Phase 2TerminatedPrimary

Study of Varespladib in Patients Hospitalized With Severe COVID-19

NCT05097677Completed

Follow-up of Covid-19 Long Term Sequelae

NCT05077969Phase 2Terminated

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients

NCT04724850CompletedPrimary

Evolution of Coronavirus Disease 2019 (COVID-19) Patients in Extremadura

NCT05897515Not ApplicableCompleted

LIAISON NES Influenza (FLU) A/B & Coronavirus Disease 2019 (COVID-19) Clinical Agreement in Australia

NCT06392451Not ApplicableNot Yet Recruiting

LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia

NCT04678830Phase 2CompletedPrimary

Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19

NCT04646044Phase 1Completed

A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19

NCT06291883Phase 1CompletedPrimary

Evaluation of KGR Prescriptions in Suppressing COVID-19 Infection.

NCT06163677Withdrawn

A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza.

NCT06189040Phase 4CompletedPrimary

Immunogenicity After COVID-19 Vaccines in Adapted Schedules

NCT05085574Phase 2Withdrawn

Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1)

NCT05107375Phase 3CompletedPrimary

Clinical Study of Recombinant Novel Coronavirus(COVID-19) Vaccine (CHO Cell) Combined With Influenza Vaccine

NCT05886829Phase 2Completed

Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III

Scroll to load more

Research Network

Activity Timeline